Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions
Joint Authors
Al Mussaed, Eman
Alzahrani, Ali Matar
Elyamany, Ghaleb
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-08-18
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin’s lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients.
PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells.
PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM).
PBL is also a therapeutic challenge with a clinical course characterized by a high rate of relapse and death.
There is no standard chemotherapy protocol for treatment of PBL.
Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like regimens have been the backbone while more intensive regimens such as cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, high-dose cytarabine (CODOX-M/IVAC), or dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) are possible options.
Recently, a few studies have reported the potential value of the proteasome inhibitor bortezomib and thalidomide in PBL patients.
The introduction of genes encoding artificial receptors called chimeric antigen receptors (CARs) and CAR-modified T cells targeted to the B cell-specific CD19 antigen have demonstrated promising results in multiple early clinical trials.
The aim of this paper is to review the recent advances in epidemiology; pathophysiology; clinical, pathologic, and molecular characteristics; therapy; and outcome in patients with PBL.
American Psychological Association (APA)
Elyamany, Ghaleb& Al Mussaed, Eman& Alzahrani, Ali Matar. 2015. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Advances in Hematology،Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1052437
Modern Language Association (MLA)
Elyamany, Ghaleb…[et al.]. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Advances in Hematology No. 2015 (2015), pp.1-11.
https://search.emarefa.net/detail/BIM-1052437
American Medical Association (AMA)
Elyamany, Ghaleb& Al Mussaed, Eman& Alzahrani, Ali Matar. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Advances in Hematology. 2015. Vol. 2015, no. 2015, pp.1-11.
https://search.emarefa.net/detail/BIM-1052437
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1052437